TRAF3 and NBR1 both influence the effect of the disease‐causing CYLD(Arg936X) mutation on NF‐κB activity by Danis, Judit et al.
Experimental Dermatology. 2021;00:1–6.   | 1wileyonlinelibrary.com/journal/exd
1  |  BACKGROUND
CYLD cutaneous syndrome (CCS) is characterized by the develop-
ment of a wide variety of skin appendage tumors, such as cylin-
dromas, trichoepitheliomas and spiradenomas, and are inherited 
in an autosomal dominant manner. Historically, descriptive names, 
including Brooke- Spiegler syndrome (BSS; OMIM 605041), familial 
cylindromatosis (FC; OMIM: 132700), and multiple familial trichoep-
ithelioma (MFT; OMIM: 601606), were assigned on the basis of the 
predominant tumor type and location, but were recently recognized 
to be a clinical spectrum of allelic conditions driven by CYLD patho-
genic variants.1,2
CYLD was localized to chromosome 16q12- 13 by genetic linkage 
analysis and fine mapping.3,4 It encodes a 956 aa tumor suppressor that 
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Abstract
Recently described Hungarian and Anglo- Saxon pedigrees that are affected by CYLD 
cutaneous syndrome (syn: Brooke- Spiegler syndrome (BSS)) carry the same disease- 
causing mutation (c.2806C>T, p.Arg936X) of the cylindromatosis (CYLD) gene but 
exhibit striking phenotypic differences. Using whole exome sequencing, missense 
genetic variants of the TRAF3 and NBR1 genes were identified in the affected family 
members of the Hungarian pedigree that are not present in the Anglo- Saxon pedigree. 
This suggested that the affected proteins (TRAF3 and NBR1) are putative phenotype- 
modifying factors. An in vitro experimental system was set up to clarify how wild 
type and mutant TRAF3 and NBR1 modify the effect of CYLD on the NF- κB signal 
transduction pathway. Our study revealed that the combined expression of mutant 
CYLD(Arg936X) with TRAF3 and NBR1 caused increased NF- κB activity, regard-
less of the presence or absence of mutations in TRAF3 and NBR1. We concluded 
that increased expression levels of these proteins further strengthen the effect of 
the CYLD(Arg936X) mutation on NF- κB activity in HEK293 cells and may explain the 
phenotype- modifying effect of these genes in CYLD cutaneous syndrome. These re-
sults raise the potential that detecting the levels of TRAF3 and NBR1 might help ex-
plaining phenotypic differences and prognosis of CCS.
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contains three Cap- Gly domains involved in protein– protein interactions 
and has a ubiquitin carboxyl- terminal hydrolase activity, with a preferen-
tial targeting of Lys- 63 (K63) linked and Met1 ubiquitin chains.5- 7
The main function of CYLD is to negatively regulate activation 
of NF- κB mediated by the tumor necrosis factor receptor (TNFR). 
The most important protein interaction partners of CYLD are NF- 
κB essential modulator (NEMO) and tumor necrosis factor receptor- 
associated factor 2 (TRAF2), both of which are target substrates of 
the deubiquitinating activity of CYLD.8,9
Distinct pathogenic variants in CYLD have been reported in >100 
families; strikingly some unrelated pedigrees with the same mutation 
have been observed to develop symptoms with different severity.10- 13 
One such hotspot is the disease- causing (rs121908390, c.2806C>T, 
p. Arg936X) pathogenic variant, resulting in a truncated form of the 
protein (p. Arg936X) in which the ubiquitin- specific processing pro-
tease histidine box is deleted.14- 16 A recent study of two families of 
Hungarian and Anglo- Saxon origins carrying this truncating mutation 
demonstrated that the same disease- causing mutation can lead to 
striking differences in severity of disease.16 To understand how the 
same underlying mutation results in differing symptoms in the two 
families, whole exome sequencing was carried out to identify the pos-
sible phenotype- modifying genetic factors causing the observed clin-
ical differences.17 Comparing the data obtained from the two families 
Pap et al17 identified three polymorphisms as potential phenotype- 
modifying variants: the rs1053023 SNP of the signal transducer and 
activator of transcription 3 (STAT3) gene, the rs1131877 SNP of the 
tumor necrosis factor receptor- associated factor 3 (TRAF3) gene and 
the rs202122812 SNP of the neighbour of BRCA1 gene 1 (NBR1) gene. 
While the STAT3 variant is located in the 3' untranslated region, the 
TRAF3 and NBR1 variants cause amino acid changes in the protein.
Tumor necrosis factor receptor- associated factor 3 is a ubiquitously 
expressed protein that functions as an E3 ubiquitin ligase, which ubiq-
uitinates target proteins, either altering their function or targeting them 
for proteasomal degradation. TRAF3 is a constitutive negative regulator 
of both canonical and alternative NF- κB pathway signalling and also acts 
as a positive regulator of type I interferon production and, thus, is a criti-
cal regulator of both innate and adaptive immune responses.18
The NBR1 protein is also ubiquitously expressed and is associ-
ated with cellular autophagy signalling pathways. NBR1 interacts 
with ubiquitin via the ubiquitin- associated (UBA) domain and has 
been proposed to function as a cargo adapter for autophagic degra-
dation of ubiquitinated substrates.19
The aim of our study was to determine whether the identified 
genes and their variants modify CYLD- mediated signal transduction 
processes.
2  |  QUESTIONS ADDRESSED
We examined the possible association of the TRAF3 rs1131877 vari-
ant and the NBR1 rs202122812 variant with the phenotypic diver-
sity of BSS. Functional studies of the causative CYLD mutation and 
of the previously predicted17 phenotype- modifying genetic factors 
were performed to determine the effect of genetic interactions and 
their role in modifying the phenotype.
We set up an in vitro experimental system and carried out func-
tional tests to answer the following question:
What are the molecular and cellular consequences of the com-
bined presence of the identified polymorphisms and how do they 
modify the effect of the CCS germline CYLD(Arg936X) mutation?
3  |  E XPERIMENTAL DESIGN
To clarify the contribution of the identified polymorphisms to modi-
fying CYLD’s role in the disease, an in vitro experimental system was 
designed. The main role of CYLD is the regulation of TNFR- mediated 
NF- κB activation. To monitor NF- κB activity, HEK293 cells were co- 
transfected with the pNFκB- luc Cis- Reporter plasmid (StrataGene), 
the pGL4.75 [hRluc/CMV] plasmid (Promega), which was used as in-
ternal control, and different combinations of the pcDNA3.1(+) vec-
tor (Invitrogen) carrying the wild type or mutant CYLD, TRAF3 and 
NBR1 cDNAs fused with tag sequences, which were added for easy 
detection by western blot. The viability of the HEK293 cells was not 
affected by the transfection with any combinations of the plasmids 
as it was assessed by MTT assay (Figure S1) and followed by regu-
lar microscopic control. The expression levels of CYLD, TRAF3 and 
NBR1 proteins were determined by western blot analyses.
Detailed description on the materials and methods are found in 
Appendix S1.
4  |  RESULTS
4.1  |  Overexpression of CYLD(Arg936X) induces 
higher NF- κB activation
To assess how wild type (WT) or mutant CYLD, TRAF3 and NBR1 
affects NF- κB signalling, HEK293 T cells were co- transfected with 
plasmids harbouring WT or mutant 3xHA- CYLD, TRAF3- HFC or NBR1- 
HFC fusion constructs together with an NF- κB firefly- luciferase re-
porter construct and an internal control plasmid expressing Renilla 
luciferase. Luciferase activities were measured 24 h after transfec-
tion, as described previously.20,21 Cells transfected with the empty 
vector pcDNA3.1(+) and luciferase vectors were used as controls in 
each experiment.
Overexpression of the WT proteins did not change NF- κB- 
induced luciferase activity, indicating that, in the cells, increased 
levels of these proteins do not affect NF- κB activity (Figure 1A). 
In contrast, overexpression of the CYLD(Arg936X) mutant protein 
resulted in an approximately threefold increase in NF- κB activity. 
Overexpression of TRAF3(Met129 Thr) and NBR1(Arg306Gln) mu-
tant proteins alone had no effect (Figure 1A).
To detect the overexpression levels of the different proteins, 
western blot analyses were carried out. All of the transfected pro-
teins were detected in the transfected cells (Figure 1B).
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4.2  |  Wild type and mutant TRAF3 or NBR1 
further increase the effect of CYLD(Arg936X) 
mutation on NF- κB activity in HEK293 cells
In a similar experimental setup, pairwise co- expression of WT CYLD 
with either WT or mutant sequences of TRAF3 or NBR1 resulted in 
no difference in NF- κB activity as compared to the control. In ad-
dition, levels in these experiments were similar to levels observed 
when these proteins were overexpressed alone. However, co- 
expression of both WT or mutant TRAF3 with CYLD(Arg936X) re-
sulted in a further 2 to 2.5- fold increase in NF- κB activity compared 
to the levels observed when mutant CYLD(Arg936X) was expressed 
alone (Figure 2A). Similarly, co- expressing CYLD(Arg936X) with 
NBR1 resulted in 1.5- to 2- fold higher NF- κB activity, regardless of 
whether the WT or mutant NBR1 sequence was used (Figure 2C).
Co- expression as detected by western blot of the combinations 
of CYLD and TRAF3 or CYLD and NBR1 proteins resulted in similar 
expression levels to those observed when the constructs were ex-
pressed individually (Figure 2B,D).
4.3  |  The combination of CYLD(Arg936X), 
TRAF3(Met129 Thr) and NBR1(Arg306Gln) mutations 
does not cause further NF- κB activation
Co- transfection of HEK 293 T cells with WT CYLD combined with 
any other plasmid construct resulted in no difference in NF- κB ac-
tivity. The combined expression of CYLD(Arg936X) both with TRAF3 
and NBR1 caused increased NF- κB activity, regardless of the latter 
two proteins were WT or mutant. However, the measured activity 
never exceeded the levels detected in the cells transfected with 
pairwise combinations of mutant CYLD and TRAF3 or NBR1 con-
structs (Figure 3A).
Similar to the pairwise combinations, in cells co- expressing all 
three transgenes (CYLD, TRAF3 and NBR1), protein levels were the 
same as in cells expressing only one construct (Figure 3B).
5  |  DISCUSSION AND CONCLUSIONS
The phenotypic variation in CCS is incompletely explained by vari-
ation in CYLD itself, and there is a clinical need to delineate modi-
fier genes that may help prognosticate disease severity for affected 
patients. Recently, unrelated family members of pedigrees of 
Hungarian and Anglo- Saxon origin affected by CCS were found to 
carry the same disease- causing mutation (c.2806C>T, p. Arg936X) 
of the CYLD gene, but exhibited striking differences in their pheno-
types.16 In this work, we aimed to reveal the putative phenotype- 
modifying effects of polymorphisms of the TRAF3 and NBR1 genes, 
which were previously identified based on whole exome sequencing 
of the Hungarian and Anglo- Saxon family members.17
The rs1131877 common SNP (global MAF = 0.266) of the TRAF3 
gene causes an amino acid change (Met129 Thr) on the N- terminal 
part of the TRAF3 protein which exhibit homology with RING do-
mains found in many E3 ubiquitin ligases and is important for li-
gase activity.22 The role of TRAF3 in cellular signalling is mediated 
mostly by direct interactions with various receptors to transmit 
the receptor signals to downstream proteins. The most prominent 
downstream interactor of TRAF3 is the TRAF- interacting protein 
(TRAIP), which is also an interacting partner of CYLD.23 One of the 
main functions of both CYLD and TRAF3 proteins is the negative 
regulation of non- canonical NF- κB activity.24 It has also been de-
scribed that mutations of CYLD and TRAF3, identified in different 
type of cancers, together can lead to constitutive activation of NF- 
κB pathway.25 Moreover, the rs1131877 SNP of the TRAF3 gene is 
highly predictive for the development of grade ≥2 acute esophageal 
postradiotherapy toxicity,26 and its association with the phenotypic 
diversity of CCS has been recently predicted.17
F I G U R E  1  Overexpression of CYLD(Arg936X) induces higher 
NF- κB activation. HEK293 cells were co- transfected with empty 
vector or plasmid constructs containing 3x- haemagglutinin 
(HA)- tagged wild type (WT) or Arg936X mutant CYLD, C- terminal 
His- Flag (HFC)- tagged WT or Met129 Thr mutant TRAF3 or 
HFC- tagged WT or Arg306Gln mutant NBR1, together with 
an NF- κB responsive firefly- luciferase reporter construct and 
a Renilla luciferase construct as an internal control. (A) Firefly 
luciferase activity was normalized to Renilla luciferase activity, and 
normalized luciferase activities were compared to the normalized 
luciferase activity of the empty vector transfected control samples. 
Statistical analysis was carried out by ANOVA and post hoc testing 
to compare luciferase activities of samples transfected by each 
mutant construct to their corresponding WT- transfected sample 
pairs. Data are represented as mean ± SD, n = 3, ****p < 0.0001. 
(B) Overexpression of the tagged proteins was demonstrated 
by western blot. To overcome possible differences between 
experiments, the same nitrocellulose membrane was probed with 
all antibodies, stripping the antibodies between. Anti- HA was used 
for visualization of CYLD, anti- FLAG was used for visualization 
of TRAF3 and NBR1, and anti- human- actin antibodies were used 
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These data supported our hypothesis that the identified TRAF3 
polymorphism may act as a phenotype- modifying genetic factor in 
CCS and prompted us to test this in an in vitro system.
Our results interestingly show that the increased level of TRAF3 
protein resulted in higher NF- κB activity only in cases when mutant 
CYLD(Arg936X) protein was also overexpressed in the cells. We ob-
served this phenomenon when either WT or mutant TRAF3 protein 
was co- expressed with the mutant CYLD(Arg936X). Our data indicate 
that increased levels of TRAF3 are important for higher NF- κB activ-
ity, regardless of the presence of the polymorphism, and higher levels 
of TRAF3 potentiate the effect of the CYLD(Arg936X) mutation. This 
synergistic effect might be mediated through the interaction of both 
CYLD and TRAF3 with TRAIP. TRAIP is an E3 ubiquitin ligase and in-
hibits TNFα mediated NF- κB activation in a manner similar to CYLD.23 
The interaction between CYLD, TRAF3 and TRAIP proteins might mu-
tually influence the ubiquitination levels of the three proteins, leading 
to increased NF- κB activity. Besides this, elevated expression level of 
TRAF3 was shown to predispose for salivary gland tumors27 where 
decreased CYLD expression and function has also been detected.28,29 
These findings together with our current results suggest an interplay 
of higher TRAF3 expression and decreased CYLD functions in CCS, 
but might also be of interest in other cancer types.
The identified rare polymorphism of the NBR1 gene (rs202122812, 
global MAF = 0.0005) causes an amino acid change (Arg306Gln), but 
it does not affect any domain with annotated function, and it has not 
been associated with any human diseases previously. However, NBR1 
is a functional homologue of the sequestosome1 (SQSTM1) protein, 
also known as the ubiquitin- binding protein p62.30 SQSTM1 functions 
as a bridge between polyubiquitinated cargo and autophagosomes, 
and it may regulate the activation of NF- κB by TNFα. Moreover, the 
interaction of CYLD with TRAF proteins that drives the deubiquitinat-
ing activity of CYLD is reduced in the absence of SQSTM1.31 CYLD 
has several putative direct targets in the NF- κB pathway, including 
NEMO, TRAF2, transforming growth factor- b activated kinase 1 
(TAK1), and TRAF6.5,6,8,32 Deubiquitinating these molecules, particu-
larly NEMO by CYLD, results in decreased NF- κB activity.6
Our experiments revealed that higher NBR1 levels further 
increase the NF- κB activity only in cells expressing the mutant 
CYLD(Arg936X) protein to similar extents, regardless of whether 
the WT or mutant NBR1 sequence was used. Based on these data, 
we conclude that NBR1 may also be a modifier of CYLD function in 
the regulation of NF- κB activity. We hypothesize that the effect of 
the CYLD mutation and the increased NBR1 level might both lead to 
decreased CYLD deubiquitinase activity on the NEMO protein and, 
as a consequence, increased NF- κB activity. Moreover, accumulation 
of NBR1 protein has been observed in breast cancer. Elevated NBR1 
expression can prevent autophagy thus elicit metastasis in cancer 
cells indicating a more general role of NBR1 in tumorous diseases.33
Since co- expression of mutant CYLD(Arg 936X) with either WT 
or mutant sequences of the TRAF3 and NBR1 proteins in triple 
combinations did not increase NF- κB activity beyond NF- κB levels 
of double combinations, we assume that there is no cooperation 
between TRAF3 and NBR1 in modifying the effects of the mutant 
CYLD(Arg936X).
These results underline the importance of functional studies 
to clarify the significance of putative phenotype- modifying fac-
tors. Although previous WES results suggested the involvement of 
TRAF3(Met129 Thr) and NBR1(Arg306Gln) in affecting the effect 
F I G U R E  2  The combined effect of CYLD(Arg936X) and TRAF3(Met129 Thr) or CYLD(Arg936X) and NBR1(Arg306Gln) mutations on 
NF- κB signalling. HEK293 cells were co- transfected with an NF- κB responsive firefly- luciferase reporter construct and a Renilla luciferase 
construct as an internal control, in pairwise combination with HA- tagged WT or Arg936X mutant CYLD either with HFC- tagged WT or 
Met129 Thr mutant TRAF3 (A, B), or with HFC- tagged WT or Arg306Gln mutant NBR1 plasmid constructs (C, D). Co- transfection with the 
empty pcDNA3.1(+) vector served as control. (A, C) Firefly luciferase activity was normalized to Renilla luciferase activity, and normalized 
luciferase activities were compared to the normalized luciferase activity of the empty vector transfected control samples. Statistical analysis 
was carried out by ANOVA and post hoc testing. Data are represented as mean ± SD, n = 3, *p < 0.05. (B, D) Overexpression of the tagged 
proteins was demonstrated by western blot. To overcome possible differences between experiments, the same nitrocellulose membrane 
was probed with all antibodies, which were stripped between analyses. Anti- HA was used for visualization of CYLD, anti- FLAG was used for 
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of the CYLD(Arg936X) in CCS,17 our functional analyses revealed no 
role for these variants, but suggested rather the importance of the 
abundance of TRAF3 and NBR1 next to the germline CYLD(Arg936X) 
mutation in CCS. Our results clearly demonstrate that only detailed 
analyses of the role of a protein can reveal clinical utility for explaining 
phenotypic differences and possibly foresee its effect in the progno-
sis of the disease. In addition, characterizing these correlations may 
promote the understanding of their mechanisms and may hopefully 
contribute to the development of future therapeutic modalities.
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